Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Video

In Partnership With:

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Gottfried Konecny, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Erin K. Crane, MD, MPH
Núria Agustí Garcia, MD
Gabriella Smith, MD
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Related Content
Robert W. Mutter, MD

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024
Article
Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023
Podcast
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article
Lionel A. Kankeu Fonkoua, MD

Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities

September 11th 2023
Podcast
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
Debra L. Richardson, MD, FACS, FACOG, associate professor, chief, Section of Gynecologic Oncology and Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma (OU) College of Medicine, OU Health

Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer

April 4th 2024
Article